Following the successful completion of 12 years of research and development between a research team at Université du Québec à Montréal (UQAM) and LUMA Life, the company has recently secured a Class II Medical Device Licence from Health Canada for its lead product, TrimX™. TrimX™ is the first ever regulatory approved and commercially available product in the field of Transcutaneous Electrical Fat Stimulation (“EFS”). TrimX™ is an easy-to-use over-the-counter (“OTC”) electrical stimulator that uses the company’s novel Adipotronics™ targeted fat loss technology.
“We are enthusiastic about this partnership with Luma, which shows that indeed it does take time before an invention reaches the market. This is a perfect example of the crucial impact of the maturation programs supported by the Québec government, which enabled de-risking the very first stages of development of the technology, in this case” explains Priyum Koonjul, Director of business development at Aligo.
The commercial launch of TrimX™ will take place on April 3rd, 2017 via the Kickstarter crowdfunding platform.
OUR PARTNER INSTITUTIONS